AuthorCitation

A phase III randomized trial of two different dosing schedules of erythropoietin (EPO) in patients with cancer-associated anemia: North Central Cancer Treatment Group (NCCTG) Study N02C2

Molina, R, Sloan, Jeff A. , Nikcevich, Daniel A., Schaefer, Paul, Rowland, Kendrith M. , Dentchev, Todor, Tschetter, Loren K., Novotny, P. J., Loprinzi, Charles L. , Steensma, David P.

Mayo Clinic

Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 8031-8031

10.1200/jco.2005.23.16_suppl.8031

A phase III double blinded, placebo controlled, randomized trial of gabapentin in patients with chemotherapy-induced peripheral neuropathy: A North Central Cancer Treatment Group study

Wong, G, Michalak, J C, Sloan, Jeff A. , Mailliard, J A, Nikcevich, Daniel A., Novotny, Paul J. , Warner, Diana, Kutteh, Leila A., Dakhil, Shaker R. , Loprinzi, Charles L.

Mayo Clinic

Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 8001-8001

10.1200/jco.2005.23.16_suppl.8001

Gemcitabine and epirubicin in patients with malignant pleural mesothelioma (MPM): A North Central Cancer Treatment Group phase II study

Okuno, Scott H. , Delaune, Robert, Sloan, Jeff A. , Aubry, Marie Christine, Foster, Nathan R. , Rowland, Kendrith M. , Mailliard, J A, Nikcevich, Daniel A., Jett, James R., Bot, Brian M.

Mayo Clinic

Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 7264-7264

10.1200/jco.2005.23.16_suppl.7264

A phase II NCCTG/CALGB trial of imatinib (STI571) in patients (pts) with c-kit-expressing relapsed small cell lung cancer (SCLC)

Dy, Grace K. , Miller, Antonius A., Mandrekar, Sumithra J. , Aubry, Marie Christine, Langdon, Robert M., Jett, James R., Adjei, Alex A. , Schild, Steven E.

Mayo Clinic

Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 7048-7048

10.1200/jco.2005.23.16_suppl.7048

Rituximab administration as part of initial therapy may be associated with a poorer outcome in young patients subsequently treated with stem cell transplantation for relapsed chemosensitive large B-cell lymphoma

Ansell, Stephen M. , Ristow, Kay M., Inwards, David J. , Micallef, Ivana N. , Porrata, Luis F. , Johnston, Patrick B. , Litzow, Mark R. , Habermann, Thomas M.

Mayo Clinic

Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 6665-6665

10.1200/jco.2005.23.16_suppl.6665

Risk of osteoporosis/osteopenia among women with breast cancer receiving anti-cancer therapy (ACT)

Boyce, Simone Peart, Mincey, Betty A., Duh, M.S., Marynchenko, Maryna, Raut, Monika , Brandman, J., Perez, Edith A.

Mayo Clinic

Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 665-665

10.1200/jco.2005.23.16_suppl.665

Gene expression signatures of conventional prognostic factors in multiple myeloma

Haug, Janine , Shammas, Masood A. , Lacy, Martha Q. , Munshi, Nikhil C. , Kumar, Subodh , Rajkumar, S. Vincent , Li, Chaofan , Dispenzieri, Angela , Gertz, Morie A. , Witzig, Thomas E. , Anderson, Kenneth C.

Mayo Clinic

Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 6606-6606

10.1200/jco.2005.23.16_suppl.6606

Circulating plasma cells detected by flow cytometry as a predictor of survival in patients with newly diagnosed multiple myeloma

Nowakowski, Grzegorz S. , Greipp, Philip R., Witzig, Thomas E. , Dingli, David , Tracz, Michał , Rajkumar, S. Vincent

Mayo Clinic

Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 6580-6580

10.1200/jco.2005.23.16_suppl.6580

Prognostic significance of the follicular lymphoma international prognostic index (FLIPI) in the E1496 trial of chemotherapy with or without maintenance rituximab

Colocci, Natalia, Weller, Edie, Hochster, H. S., Gascoyne, Randall D., Kumm, B., Frankel, SR, Horning, SJ, Ryan, T., Habermann, Thomas M.

Mayo Clinic

Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 6526-6526

10.1200/jco.2005.23.16_suppl.6526

Anti-tumor activity of low-dose single agent CCI-779 for relapsed mantle celllLymphoma: A phase II trial in the North Central Cancer Treatment Group

Ansell, Stephen M. , Geyer, Susan M. , Kurtin, Paul J. , Rowland, Kendrith M. , Flynn, Patrick J. , Morton, Roscoe F., Dakhil, Shaker R. , Gross, Howard M., Witzig, Thomas E. , Maurer, Matthew J. , Kaufmann, Scott H.

Mayo Clinic

Journal of Clinical Oncology | February 23, 2017 | Volume: 23 | Issue: 16_suppl | Pages: 6504-6504

10.1200/jco.2005.23.16_suppl.6504

Citations

A phase III randomized trial of two different dosing schedules of erythropoietin (EPO) in patients with cancer-associated anemia: North Central Cancer Treatment Group (NCCTG) Study N02C2

Molina, R, Sloan, Jeff A. , Nikcevich, Daniel A., Schaefer, Paul, Rowland, Kendrith M. , Dentchev, Todor, Tschetter, Loren K., Novotny, P. J., Loprinzi, Charles L. , Steensma, David P.

A phase III double blinded, placebo controlled, randomized trial of gabapentin in patients with chemotherapy-induced peripheral neuropathy: A North Central Cancer Treatment Group study

Wong, G, Michalak, J C, Sloan, Jeff A. , Mailliard, J A, Nikcevich, Daniel A., Novotny, Paul J. , Warner, Diana, Kutteh, Leila A., Dakhil, Shaker R. , Loprinzi, Charles L.

Gemcitabine and epirubicin in patients with malignant pleural mesothelioma (MPM): A North Central Cancer Treatment Group phase II study

Okuno, Scott H. , Delaune, Robert, Sloan, Jeff A. , Aubry, Marie Christine, Foster, Nathan R. , Rowland, Kendrith M. , Mailliard, J A, Nikcevich, Daniel A., Jett, James R., Bot, Brian M.

A phase II NCCTG/CALGB trial of imatinib (STI571) in patients (pts) with c-kit-expressing relapsed small cell lung cancer (SCLC)

Dy, Grace K. , Miller, Antonius A., Mandrekar, Sumithra J. , Aubry, Marie Christine, Langdon, Robert M., Jett, James R., Adjei, Alex A. , Schild, Steven E.

Rituximab administration as part of initial therapy may be associated with a poorer outcome in young patients subsequently treated with stem cell transplantation for relapsed chemosensitive large B-cell lymphoma

Ansell, Stephen M. , Ristow, Kay M., Inwards, David J. , Micallef, Ivana N. , Porrata, Luis F. , Johnston, Patrick B. , Litzow, Mark R. , Habermann, Thomas M.

Risk of osteoporosis/osteopenia among women with breast cancer receiving anti-cancer therapy (ACT)

Boyce, Simone Peart, Mincey, Betty A., Duh, M.S., Marynchenko, Maryna, Raut, Monika , Brandman, J., Perez, Edith A.

Gene expression signatures of conventional prognostic factors in multiple myeloma

Haug, Janine , Shammas, Masood A. , Lacy, Martha Q. , Munshi, Nikhil C. , Kumar, Subodh , Rajkumar, S. Vincent , Li, Chaofan , Dispenzieri, Angela , Gertz, Morie A. , Witzig, Thomas E. , Anderson, Kenneth C.

Circulating plasma cells detected by flow cytometry as a predictor of survival in patients with newly diagnosed multiple myeloma

Nowakowski, Grzegorz S. , Greipp, Philip R., Witzig, Thomas E. , Dingli, David , Tracz, Michał , Rajkumar, S. Vincent

Prognostic significance of the follicular lymphoma international prognostic index (FLIPI) in the E1496 trial of chemotherapy with or without maintenance rituximab

Colocci, Natalia, Weller, Edie, Hochster, H. S., Gascoyne, Randall D., Kumm, B., Frankel, SR, Horning, SJ, Ryan, T., Habermann, Thomas M.

Anti-tumor activity of low-dose single agent CCI-779 for relapsed mantle celllLymphoma: A phase II trial in the North Central Cancer Treatment Group

Ansell, Stephen M. , Geyer, Susan M. , Kurtin, Paul J. , Rowland, Kendrith M. , Flynn, Patrick J. , Morton, Roscoe F., Dakhil, Shaker R. , Gross, Howard M., Witzig, Thomas E. , Maurer, Matthew J. , Kaufmann, Scott H.